This case report evaluated dupilumab (an IL-4/IL-13 receptor antagonist) in a child with severe asthma and refractory allergic bronchopulmonary aspergillosis (ABPA) that had not responded adequately to standard therapies.
Dupilumab was effective in managing both severe asthma and refractory ABPA in this pediatric patient, suggesting a potential role for IL-4/IL-13 blockade in this dual-diagnosis setting.
Single case report limits generalizability; no control or comparator; long-term follow-up data are not described.
In children with severe asthma and refractory ABPA failing conventional treatment, dupilumab may offer meaningful disease control. Clinicians should consider biologic options early in this challenging overlap syndrome.
